Serotonin Syndrome: A Mix of Medicines That Can Be Lethal
“Catastrophic side effects may be rare, but they become predictable when we treat so many children with so many drugs.”
“Catastrophic side effects may be rare, but they become predictable when we treat so many children with so many drugs.”
The question is can these visits overcome industry's propaganda delivered under the guise of continuing medical education (CME) courses which physicians must take?
The deceptive marketing of antipsychotic drugs has prompted new advocacy group to launch "The Just Say "Know" to Prescription Drugs Campaign." Its goal is to get one million people to stop and reevaluate the medications they are taking.
A commentary in the April 2007 issue of HARVAD magazine, AHRP board member, Stefan Kruszeuski, MD, urges his colleagues to abandon psychiatry’s diagnostic and therapeutic reductionism.
Drug safety is a public issue–and the FDA has been shown to be asleep at the helm as tens of thousands have died that could have lived had they and their physicians known the safety hazards of prescribed drugs.
The shift from Hippocratic medicine grounded in the “do no harm” principle, to corporate medicine has severed the unique physician-patient relationship based on a tacit understanding that the physician’s reasoned therapeutic recommendations will be governed the patient’s best interest.
What does the "Gillberg affair" suggest about the integrity of the data underlying the DAMP-ADHD hypothesis?
The pharmaceutical industry’s latest antidepression drug marketing campaign is being launched with collaboration of the National Institute of Mental Health (NIMH) “Real Men, Real Depression campaign http://menanddepression.nimh.nih.gov/infopage.asp?ID=1
“To me one of the miracle of children’s brains is that we don’t see more harm from these treatments.”
Good News–Merck caved under backlash.
The pharmaceutical industry’s latest antidepression drug marketing campaign is being launched with collaboration of the National Institute of Mental Health (NIMH)—
China is probably not a good place for the pharmaceutical industry–unless companies are willing to market their products without engaging in fraud…